Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance.

By M. Fuertes, C. Alonso, J. Pérez. Chemical Reviews, 2003

829 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cisplatin: The first metal based anticancer drug. (2019, background): “activating factor 1) and ATP (adenosine triphosphate) to form an apoptosome complex which activates caspase-9 [42].”
Cellular processing of platinum anticancer drugs (2005, background): “Among these many compounds, only one has been approved by the FDA: oxaliplatin, for the treatment of colorectal cance”
Copper complexes as anticancer agents. (2009, background): “The combined interest in (i) improving the DNA cleavage specificity of (52) type complexes together with their ability to perform double-strand breaks (DSB) and (ii) circumventing drug resistance owing to the use of cisplatin [190-194] inspired the design of bifunctional molecules (53a) and (53b) [1”
Molecular mechanisms of resistance and toxicity associated with platinating agents. (2007, background): “All crosslinks result in contortion of the DNA (reviewed in [10]).”